Final answer:
The medications included in the ASRA guidelines are anticoagulants rivaroxaban (Xarelto) and dabigatran (Pradaxa). Clopidogrel is noted as an antiplatelet drug commonly used in dual antiplatelet therapy.
Step-by-step explanation:
Among the medications listed, the rivaroxaban and dabigatran are included in the American Society of Regional Anesthesia (ASRA) guidelines. These medications are anticoagulants used many times in the context of preventing thrombosis (the formation of a blood clot inside a blood vessel). Rivaroxaban (Xarelto) is a direct Factor Xa inhibitor, while dabigatran (Pradaxa) is a direct thrombin inhibitor.
Clopidogrel is an antiplatelet medication that is often prescribed for use in dual antiplatelet therapy (DAPT), especially after procedures like coronary stent placement, to prevent thrombotic events. Ticlopidine is another antiplatelet drug that has been largely supplanted by newer medications due to its side effect profile.
The ASRA guidelines provide detailed recommendations on the use of antithrombotic and thrombolytic therapy in patients undergoing regional anesthesia and pain medicine procedures. These guidelines aim to minimize the risk of bleeding complications while ensuring effective antithrombotic therapy.